Mira Pharmaceuticals' Oral Mira-55 Outperforms Morphine in Pain Relief and Inflammation Reduction, Preclinical Study Shows
Mira Pharmaceuticals Inc. has announced new preclinical research results for its proprietary non-psychotropic marijuana analog, Mira-55. According to the company, oral administration of Mira-55 fully normalized pain and significantly reduced inflammation in an established animal model of chronic inflammatory pain, outperforming injected morphine. The study is notable as the first in the Mira-55 program to directly measure both pain and inflammation. Mira-55, administered orally, restored pain thresholds to baseline levels and showed a direct CB2-receptor-mediated anti-inflammatory effect, whereas morphine provided only partial and indirect inflammation reduction. These findings support Mira Pharmaceuticals' plans to pursue an Investigational New Drug (IND) application for treating chronic inflammatory pain. The announcement does not specify if or when these results will be presented at a scientific conference.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mira Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-25-018141), on October 15, 2025, and is solely responsible for the information contained therein.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。